<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01331161</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00050285</org_study_id>
    <secondary_id>U19AI090023</secondary_id>
    <secondary_id>HIPCVAX005</secondary_id>
    <nct_id>NCT01331161</nct_id>
  </id_info>
  <brief_title>Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly</brief_title>
  <official_title>Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vaccination is the most effective way of preventing infectious diseases. Despite the success
      of vaccines in general, vaccines induce diminished antibody responses and lower protection in
      the elderly in particular. This could be explained by a defect in the early responses of an
      ageing immune system. A better understanding of the basic immunological mechanisms that
      mediate vaccine efficacy is incomplete. Such information is critical and could greatly
      decrease both the cost and the time to new vaccine development particularly for the geriatric
      population.

      In this trial, the investigators will study the immunologic differences of the FDA approved
      licensed shingles vaccine between a younger and an older group. Thirty three healthy
      volunteers between the ages of 25-40 and forty four healthy volunteers between the ages of
      60-79 will be enrolled in the study. Each participant in the study will be given one shingles
      shot. Blood work will be obtained one month before vaccination, on the day of vaccination,
      one day, three days, seven days, fourteen days, one month, three months and six months after
      vaccination. Throughout the duration of the study, the participants will be monitored for
      safety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RATIONALE: Zoster vaccine is known to induce diminished antigen-specific T cell responses and
      lower protection in the elderly. Here we hypothesize that this is due to intrinsic defects in
      innate responses to the live attenuated virus, which translates into sub-optimal functional
      adaptive immune responses. Therefore, early innate signatures of vaccination should correlate
      with, and predict the immunogenicity of Zoster vaccine in the young and elderly.

      STUDY DESIGN: Double center, open label study in which adult healthy volunteers will be
      vaccinated with Zoster vaccine. Blood samples will be collected on day D-30 (pre-
      vaccination) D0 (at vaccination) and D1, D3, D7, D14, D30, D90 and D180 (post vaccination) to
      study innate and adaptive immunity responses. Even though Zoster vaccine is considered safe,
      volunteers are asked to report and record any local or systemic AEs for 7 days
      post-vaccination. Also AEs will be reported for 30 days post-vaccination any SAE for 180 days
      post vaccination. AEs developing the day of the blood draw will also be reported
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Innate Immunity Signatures That Correlate With the T Cell Adaptive Immunity Responses After ZOSTAVAX</measure>
    <time_frame>2 years</time_frame>
    <description>The primary outcomes will identify the number of participants with innate immunity signatures in the young and older groups that correlate with the T cell adaptive immunity responses after ZOSTAVAX</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants With Innate Immune Signatures That Correlate With the B and T Cells Adaptive Immunity Responses After ZOSTAVAX</measure>
    <time_frame>2 years</time_frame>
    <description>The number of participants with innate immune signatures in the young and old groups that correlate with the B and T cells adaptive immunity responses after ZOSTAVAX</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Shingles</condition>
  <arm_group>
    <arm_group_label>Older group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants between the ages of 60-79</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Younger group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants between the ages of 25-40</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ZOSTAVAX</intervention_name>
    <description>shingles vaccine, one dose</description>
    <arm_group_label>Older group</arm_group_label>
    <arm_group_label>Younger group</arm_group_label>
    <other_name>shingles vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to understand and give informed consent.

          -  Immunocompetent subjects aged 25-40 years, or community dwelling subjects between the
             ages of 60-79.

        Exclusion Criteria:

          -  Young adults aged 25-40 years who are Varicella-Zoster virus seronegative or equivocal
             results (mean value OD for Varicella-Zoster virus IgG lower than 1.1 by commercial
             enzyme-linked immunosorbent assay (ELISA) (Hope Clinic: IgG VZV ELISAII-Wampole
             Laboratories®, NJ, USA- Vaccine Research Trials Center:: Liaison VZV IgG Assay,
             DiaSorin, Italy)

          -  Receipt of immune products:

               -  Receipt of blood products within 6 months prior to vaccination with Zoster
                  vaccine or expected receipt through 6 months after vaccination with Zoster
                  vaccine*

               -  Receipt of any vaccine within 4 weeks prior to vaccination with Zoster vaccine or
                  expected receipt within 4 weeks after vaccination with Zoster vaccine*

               -  Receipt of Zoster vaccine or varicella vaccines at any time prior to study entry.

          -  Subject taking any non-topical antiviral therapy with activity against herpes viruses,
             including but not limited to acyclovir, famciclovir, valacyclovir, and ganciclovir 3
             days prior to vaccination or 14 days after*.

          -  Prior history of shingles.

          -  Presence of certain co morbidities or immunosuppressive states such as:

               -  Chronic medical problems including (but not limited to) insulin-dependent
                  diabetes, severe heart, lung, liver, or kidney diseases; auto immune diseases;
                  severe gastrointestinal diseases; and uncontrolled hypertension.

               -  Alcohol or drug abuse and psychiatric conditions that in the opinion of the
                  investigator would preclude compliance with the trial or interpretation of safety
                  or endpoint data.

               -  Impaired immune function or chronic infections including (but not limited to)
                  HIV, hepatitis B or C, tuberculosis, organ transplant, cancer, current and or
                  expected receipt of chemotherapy, radiation therapy, steroids [i.e., &gt; 20 mg of
                  prednisone given daily or on alternative days for 2 weeks or more in the past 90
                  days*); (nasal and topical steroids are allowed)],antitumor necrosis factor
                  agents, or any other immunosuppressive therapy, anatomic or functional asplenia,
                  congenital immunodeficiency.

               -  Pregnant or breast-feeding women, or women expecting to conceive 30 days before
                  and 90 days after vaccination**.

          -  Conditions that could affect the safety of the volunteers such as:

               -  Severe reactions to prior vaccinations.

               -  History of anaphylactic/anaphylactoid reaction to gelatin, neomycin or any other
                  component of the vaccine. Neomycin allergy manifested as contact dermatitis is
                  not a contraindication to receiving this vaccine.

               -  History of bleeding disorders

          -  Any acute illness, including any fever (&gt; 100.4 F [&gt; 38.0C], regardless of the route)
             within 3 days prior to study entry *.

          -  Social, occupational, or any other condition that in the opinion of the investigator
             might interfere with compliance with the study and vaccine evaluation.

        Note:

        *An individual who initially is excluded from study participation based on one or more of
        the time-limited exclusion criteria (e.g., acute illness, receipt or expected receipt of
        live or inactivated vaccines ) may be considered for enrollment once the condition has
        resolved as long as the subject continues to meet all other entry criteria.

        Subjects receiving &gt; 20 mg/day of prednisone or its equivalent daily or on alternate days
        for more than 2 weeks may enter the study after therapy has been discontinued for more than
        3 months.

        **Women of child-bearing potential (not surgically sterile via tubal ligation, bilateral
        oophorectomy or hysterectomy or who are not postmenopausal for ≥1 year) must agree to
        practice adequate contraception that may include, but is not limited to, relationship with
        vasectomized partner, barrier methods such as condoms, diaphragms, spermicides,
        intrauterine devices, and licensed hormonal methods for 30 days before and 90 days after
        zoster vaccination.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadine Rouphael, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2011</study_first_submitted>
  <study_first_submitted_qc>April 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2011</study_first_posted>
  <results_first_submitted>January 19, 2016</results_first_submitted>
  <results_first_submitted_qc>January 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 17, 2016</results_first_posted>
  <disposition_first_submitted>April 23, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>April 23, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 1, 2013</disposition_first_posted>
  <last_update_submitted>January 19, 2016</last_update_submitted>
  <last_update_submitted_qc>January 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Nadine Rouphael</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>shingles vaccine</keyword>
  <keyword>immune responses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from Atlanta and Denver from July 2011 until March 2012 using flyers</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Older Group</title>
          <description>Participants between the ages of 60-79
ZOSTAVAX: shingles vaccine, one dose</description>
        </group>
        <group group_id="P2">
          <title>Younger Group</title>
          <description>Participants between the ages of 25-40
ZOSTAVAX: shingles vaccine, one dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Age 60-79 Years</title>
          <description>Participants between the ages of 60-79 years received a single dose of the Zoster vaccine (ZOSTAVAX®) subcutaneously.</description>
        </group>
        <group group_id="B2">
          <title>Age 25-40 Years</title>
          <description>Participants between the ages of 25-40 years received a single dose of the Zoster vaccine (ZOSTAVAX®) subcutaneously.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="77"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="60" upper_limit="77"/>
                    <measurement group_id="B2" value="33" lower_limit="25" upper_limit="40"/>
                    <measurement group_id="B3" value="61" lower_limit="25" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Innate Immunity Signatures That Correlate With the T Cell Adaptive Immunity Responses After ZOSTAVAX</title>
        <description>The primary outcomes will identify the number of participants with innate immunity signatures in the young and older groups that correlate with the T cell adaptive immunity responses after ZOSTAVAX</description>
        <time_frame>2 years</time_frame>
        <population>participants with immunoglobulin gene responses that correlated with adaptive immune responses</population>
        <group_list>
          <group group_id="O1">
            <title>Participants 60-79 Years</title>
            <description>participants who received one dose of vaccine</description>
          </group>
          <group group_id="O2">
            <title>Participants 25-40 Years of Age</title>
            <description>participants with one dose of vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Innate Immunity Signatures That Correlate With the T Cell Adaptive Immunity Responses After ZOSTAVAX</title>
          <description>The primary outcomes will identify the number of participants with innate immunity signatures in the young and older groups that correlate with the T cell adaptive immunity responses after ZOSTAVAX</description>
          <population>participants with immunoglobulin gene responses that correlated with adaptive immune responses</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants With Innate Immune Signatures That Correlate With the B and T Cells Adaptive Immunity Responses After ZOSTAVAX</title>
        <description>The number of participants with innate immune signatures in the young and old groups that correlate with the B and T cells adaptive immunity responses after ZOSTAVAX</description>
        <time_frame>2 years</time_frame>
        <population>Participants with both T and B cell responses to vaccine</population>
        <group_list>
          <group group_id="O1">
            <title>Age 60-79 Years</title>
            <description>Participants between the ages of 60-79 years received a single dose of the Zoster vaccine (ZOSTAVAX®) subcutaneously.</description>
          </group>
          <group group_id="O2">
            <title>Age 25-40 Years</title>
            <description>Participants between the ages of 25-40 years received a single dose of the Zoster vaccine (ZOSTAVAX®) subcutaneously.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With Innate Immune Signatures That Correlate With the B and T Cells Adaptive Immunity Responses After ZOSTAVAX</title>
          <description>The number of participants with innate immune signatures in the young and old groups that correlate with the B and T cells adaptive immunity responses after ZOSTAVAX</description>
          <population>Participants with both T and B cell responses to vaccine</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Older Group</title>
          <description>Participants between the ages of 60-79
ZOSTAVAX: shingles vaccine, one dose</description>
        </group>
        <group group_id="E2">
          <title>Younger Group</title>
          <description>Participants between the ages of 25-40
ZOSTAVAX: shingles vaccine, one dose</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <description>resulted in hospitalization- unrelated to study product</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <description>Breast cancer unrelated to study product</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cold symptoms</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>None related to study product- severity varied between 1 to 3 - all resolved</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Local Injection site reactions</sub_title>
                <description>All were attributed as related to study product- severity was between 1 and 2- all resolved</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Bruise at blood draw site</sub_title>
                <description>realted to phlebotomy intervention- all resolved</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nadine Rouphael, MD</name_or_title>
      <organization>Emory University</organization>
      <phone>404-712-1435</phone>
      <email>nroupha@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

